Nasdaq · Healthcare

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)

As-reported financials and recent SEC filings for PACIFIC BIOSCIENCES OF CALIFORNIA, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$160.0M

Net income

$-546.4M

Net margin

—

Diluted EPS

$-1.82

ROE

-10214.5%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$160.0M	$154.0M	$200.5M	$128.3M	$130.5M
Gross profit	$45.8M	$37.3M	$52.8M	$49.0M	$58.9M
Operating income	$-553.9M	$-474.3M	$-334.5M	$-307.2M	$-210.4M
Net income	$-546.4M	$-309.9M	$-306.7M	$-314.2M	$-181.2M
Diluted EPS	$-1.82	$-1.59	$-1.21	$-1.40	$-0.89

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-04

42026-06-04

42026-06-04

42026-06-04

42026-06-04

42026-06-04

42026-06-04

42026-06-04

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on PACB

Search PACIFIC BIOSCIENCES OF CALIFORNIA, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.